剑指体内 CAR-T 疗法领域！该头部药企斥资21亿美元收购

制药网

2025/07/01

【制药网企业新闻】近日，艾伯维(AbbVie)宣布了一项重大战略决策，将以 21 亿美元现金收购临床阶段生物技术公司 Capstan Therapeutics。这一举措标志着艾伯维正式进军体内 CAR-T 疗法领域，有望为自身免疫性疾病及其他疾病的治疗带来革新。Capstan Therapeutics专注于开发前沿的体内细胞疗法。其核心技术是利用靶向脂质纳米颗粒(tLNP)递送 RNA，实现对...

网页链接

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2548902413"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2548902413\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2548902413?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":false,"pubTime":"2025-07-01 13:51","share_image_url":"https://static.laohu8.com/9a95c1376e76363c1401fee7d3717173","id":"2548902413","market":"us","top_or_hot":-1,"title":"剑指体内 CAR-T 疗法领域！该头部药企斥资21亿美元收购","media":"制药网","content":"<div>\n<p>【制药网 企业新闻】近日，艾伯维(AbbVie)宣布了一项重大战略决策，将以 21 亿美元现金收购临床阶段生物技术公司 Capstan Therapeutics。这一举措标志着艾伯维正式进军体内 CAR-T 疗法领域，有望为自身免疫性疾病及其他疾病的治疗带来革新。Capstan Therapeutics专注于开发前沿的体内细胞疗法。其核心技术是利用靶向脂质纳米颗粒(tLNP)递送 RNA，实现对...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025070113533395322623&s=b\">网页链接</a>\n\n</div>\n","source":"tencent","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>剑指体内 CAR-T 疗法领域！该头部药企斥资21亿美元收购</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n剑指体内 CAR-T 疗法领域！该头部药企斥资21亿美元收购\n</h2>\n\n<h4 class=\"meta\">\n\n\n2025-07-01 13:51 北京时间&nbsp;&nbsp;&nbsp;<a href=http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025070113533395322623&s=b><strong>制药网</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>【制药网 企业新闻】近日，艾伯维(AbbVie)宣布了一项重大战略决策，将以 21 亿美元现金收购临床阶段生物技术公司 Capstan Therapeutics。这一举措标志着艾伯维正式进军体内 CAR-T 疗法领域，有望为自身免疫性疾病及其他疾病的治疗带来革新。Capstan Therapeutics专注于开发前沿的体内细胞疗法。其核心技术是利用靶向脂质纳米颗粒(tLNP)递送 RNA，实现对...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025070113533395322623&s=b\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"SG9999011175.SGD","symbol_name":"Nikko AM Global Dividend Equity Dis SGD-H","start_time":0,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025070113533395322623&s=b","article_id":"2548902413","we_media_id":null,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025070113533395322623&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2548902413","pubTimestamp":1751349073,"columns":[],"sourceInfo":{"source_id":"tencent","name":"腾讯"},"weMediaInfo":null,"summary":"Capstan Therapeutics 的主要资产 CPTX2309 是一款具潜力的体内 tLNP 抗 CD19 CAR-T 疗法候选药物。各大药企的积极布局，充分显示出体内 CAR-T 疗法在未来疾病治疗中的巨大潜力。若 CPTX2309 在后续临床试验中能够成功验证人体安全性和有效性，CAR-T 疗法有望从目前的 “天价特药” 逐渐转变为更具普惠性的药物，重塑免疫疾病治疗格局。","collect":0,"end_time":0,"defaultTopTitle":"qq.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"SG9999011175.SGD":"Nikko AM Global Dividend Equity Dis SGD-H","LU2089284900.SGD":"Allianz Global Sustainability Cl AM Dis H2-SGD","SG9999003800.SGD":"Nikko AM Global Dividend Equity Acc SGD-H","LU0943347566.SGD":"安联收益及增长平衡基金AM H2-SGD","LU0122379950.USD":"贝莱德世界健康科学A2","CAR":"安飞士","LU0234572021.USD":"高盛美国核心股票组合Acc","LU0456855351.SGD":"JPMorgan Funds - Global Equity A (acc) SGD","LU1074936037.SGD":"JPMorgan Funds - US Value A (acc) SGD","LU0211327993.USD":"TEMPLETON GLOBAL EQUITY INCOME \"A\" (USD) ACC","SG9999015945.SGD":"LionGlobal Disruptive Innovation Fund A SGD","LU0965509010.AUD":"AB LOW VOLATILITY EQUITY PORTFOLIO \"AD\" (AUDHDG) INC","LU2237443382.USD":"Aberdeen Standard SICAV I - Global Dynamic Dividend A MIncA USD","LU2468319806.SGD":"MANULIFE GF HEALTHCARE \"AA\" (SGDHDG) ACC","LU0203345920.USD":"SCHRODER ISF QEP GLB ACT. VL \"A\" (USD) ACC","LU0795875169.SGD":"JPMorgan Investment Funds - Global Income A (div) SGD-H","BK4585":"ETF&股票定投概念","LU1496350171.SGD":"FRANKLIN DIVERSIFIED BALANCED \"A\" (SGDHDG) ACC","LU2237443895.HKD":"abrdn SICAV I -  GLOBAL DYNAMIC DIVIDEND \"A\" (HKD) ACC","LU1037948897.HKD":"AB LOW VOLATILITY EQUITY PORTFOLIO \"AD\" (HKD) INC","LU1430594728.SGD":"Eastspring Investments - Global Low Volatility Equity AS SGD","ABBV":"艾伯维公司","LU2237443465.HKD":"abrdn SICAV I -  GLOBAL DYNAMIC DIVIDEND \"A\" (HKD) INC","LU0310800379.SGD":"FTIF - Templeton Global A Acc SGD","IE00B2B36J28.USD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I1\" (USD) INC","LU0965508806.USD":"AB LOW VOLATILITY EQUITY PORTFOLIO \"AD\" (USD) INC","LU2237443622.USD":"Aberdeen Standard SICAV I - Global Dynamic Dividend A Acc USD","BK4534":"瑞士信贷持仓","LU0949170772.SGD":"Blackrock Global Equity Income A6 SGD-H","BK4139":"生物科技","LU2237443978.SGD":"Aberdeen Standard SICAV I - Global Dynamic Dividend A Acc SGD-H","BK4533":"AQR资本管理(全球第二大对冲基金)","LU1003077747.HKD":"BGF GLOBAL EQUITY INCOME \"A6\" (HKDHDG) INC","IE00BGHQF631.EUR":"GUINNESS GLOBAL EQUITY INCOME \"C\" (EUR) ACC","LU0985320562.USD":"NORDEA 1 GLOBAL STARS EQUITY \"BP\" (USD) ACC","BK4566":"资本集团","SG9999015952.SGD":"LIONGLOBAL DISRUPTIVE INNOVATION \"I\" (SGD) ACC","LU2112291526.USD":"BGF WORLD HEALTHSCIENCE \"A4\" (USD) INC","LU1934455194.USD":"AB SICAV I LOW VOLATILITY TOTAL RETURN EQUITY PORT \"A\" (USD) ACC","LU1839511570.USD":"WELLS FARGO GLOBAL FACTOR ENHANCED EQUITY \"I\" (USD) ACC","IE00B19Z3581.USD":"Legg Mason ClearBridge - Value A Acc USD","IE00B3PB1722.GBP":"GUINNESS GLOBAL EQUITY INCOME \"C\" (GBP) INC","LU0256863902.USD":"ALLIANZ US EQUITY \"AT\" (USD) ACC","LU2133065610.SGD":"JPMorgan Investment Funds - Global Dividend A (mth) SGD","IE00B42XCP33.USD":"GUINNESS GLOBAL EQUITY INCOME \"C\" (USD) INC","LU1551013342.USD":"Allianz Income and Growth Cl AMg2 DIS USD","LU0738911758.USD":"Blackrock Global Equity Income A6 USD","LU0795875086.SGD":"JPMorgan Investment Funds - Global Income A (div) SGD","BK4550":"红杉资本持仓","LU0029864427.USD":"TEMPLETON GLOBAL \"A\" (USD) INC"},"translate_title":"The sword refers to the field of CAR-T therapy in vivo! The leading pharmaceutical company spent $2.1 billion to acquire","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ABBV":0.9,"CAR":1},"content_text":"【制药网 企业新闻】近日，艾伯维(AbbVie)宣布了一项重大战略决策，将以 21 亿美元现金收购临床阶段生物技术公司 Capstan Therapeutics。这一举措标志着艾伯维正式进军体内 CAR-T 疗法领域，有望为自身免疫性疾病及其他疾病的治疗带来革新。Capstan Therapeutics专注于开发前沿的体内细胞疗法。其核心技术是利用靶向脂质纳米颗粒(tLNP)递送 RNA，实现对体内细胞的精准工程化改造。这一技术平台旨在将 mRNA 等 RNA 有效载荷递送至特定细胞类型，开启了细胞疗法的全新路径。Capstan Therapeutics 的主要资产 CPTX2309 是一款具潜力的体内 tLNP 抗 CD19 CAR-T 疗法候选药物。该疗法目前正处于 1 期临床试验阶段，致力于治疗 B 细胞介导的自身免疫性疾病。在自身免疫性疾病中，免疫系统错误地攻击自身组织，导致慢性炎症和组织损伤。B 细胞在这一过程中扮演着重要角色，而 CD19 是 B 细胞表面的关键受体，成为治疗自身免疫疾病中 B 细胞耗竭的理想靶点。CPTX2309 借助 Capstan 专有的 tLNP 平台技术，特别是肝脏去靶向技术，能够优先将编码抗 CD19 CAR 的 mRNA 有效载荷递送至表达 CD8 的细胞毒性 T 细胞。这种独特的体内编程方式，使得细胞毒性 T 细胞被重编程为能够识别并清除表达 CD19 的 B 细胞，从而实现对自身免疫疾病的治疗。与传统 CAR-T 疗法相比，CPTX2309 无需进行复杂的体外细胞改造以及淋巴耗竭预处理，大大简化了治疗流程，缩短了治疗周期，从传统的数周缩短至数小时，同时有望将治疗成本降低至传统 CAR-T 的 1/10，显著提高了治疗的可及性。对于艾伯维而言，此次收购具有深远的战略意义。近年来，艾伯维面临着严峻的 “专 利悬崖” 挑战。其曾经的 “药王” 修美乐(Humira)自专 利到期后，销售额持续下滑，2024 年同比暴跌 37.6%。肿瘤药物伊布替尼(Imbruvica)也因二代竞品的挤压，增长势头受到抑制。在这样的背景下，艾伯维急需开拓新的治疗领域，寻找具有突破性的技术和产品，以重塑公司的护城河。Capstan Therapeutics 的技术和产品与艾伯维在免疫学和肿瘤学领域的战略布局高度契合。通过收购 Capstan，艾伯维不仅获得了 CPTX2309 这一具潜力的自身免疫疾病治疗候选药物，还有望借助 Capstan 的 tLNP 平台技术，进一步拓展其在肿瘤治疗领域的管线。tLNP 平台技术具有高度的灵活性，能够快速更换靶点，为开发针对不同疾病的细胞疗法提供了可能。艾伯维相关人士表示，通过推进 CPTX2309 并利用 Capstan 的新型平台技术，艾伯维和 Capstan 旨在通过开发有可能重置免疫系统的治疗方法来改变对自身免疫性疾病患者的护理。这一表态明确了艾伯维在自身免疫疾病治疗领域的决心和目标。艾伯维对 Capstan Therapeutics 的收购，在生物医药行业引发了广泛关注。这一交易不仅刷新了近期生物医药并购的规模纪录，更标志着 “体内生成 CAR-T” 技术成为众多药企竞相角逐的焦点领域。此前，阿斯利康已斥资 10 亿美元收购 EsoBiotec(专注于慢病毒载体体内 CAR-T)，诺华、强生等药企也纷纷在该领域加大投入。各大药企的积极布局，充分显示出体内 CAR-T 疗法在未来疾病治疗中的巨大潜力。若 CPTX2309 在后续临床试验中能够成功验证人体安全性和有效性，CAR-T 疗法有望从目前的 “天价特药” 逐渐转变为更具普惠性的药物，重塑免疫疾病治疗格局。对于 Capstan Therapeutics 而言，被艾伯维收购后，将获得更雄厚的资金支持和更广泛的研发资源，加速推进 CPTX2309 以及其他在研项目的临床开发进程。而对于艾伯维来说，此次收购是其在创新疗法领域的一次重大战略突破，有望为公司的长期发展注入新的活力，在激烈的市场竞争中抢占先机。","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"2","news_tag":"corporation,merge","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"}}}